

# IMI2 - Call 15: Digital endpoints in neurodegenerative and immune-mediated diseases

Jul 18, 2018



First Name	Last Name	Email	Country	Organisation	Briefly, what would you bring to the project in terms of expertise, resources, activities?
Peter	Annas	peter.annas@camcog.com	United Kingdom	Cambridge Cognition Ltd	Digital technologies for measuring cognitive function.
Antonis	Billis	antonis.mpillis@gmail.com	Greece	AUTH	
Marta	Burgos Gonzalez	proyectos@parkinsonmadrid.org	Spain	ASOCIACION PARKINSON MADRID	In direct touch with end users, beneficiaries. 1800 patients affected by PD and expertise in establishing the needs
Célia	Cabral	celia.cabral@fmed.uc.pt	Portugal	Faculdade de Medicina, Universidade de Coimbra	
Kallol Ray	Chaudhuri	dhaval.trivedi1@nhs.net	United Kingdom	King's College London	Neurodegenerative disease expertise, All technology based research, input from all research publication, global research partners
Alexandra	Chukas	alexandra.chukas@icm-institute.org	France	ICM	
Francesca	Cormack	francesca.cormack@camcog.com	United Kingdom	Cambridge Cognition	experience in developing digital endpoints and assessments of cognitive function, particularly in neurodegenerative disease
Renata	De Maria	renata_de_maria@hotmail.com	Italy	CNR Clinical Physiology Institute	
Richard	Dobson	richard.j.dobson@kcl.ac.uk	United Kingdom	Kind College London	Software platform for mHealth developed from RADAR-CNS
Javier	Ferris	javier.ferris@ibv.org	Spain	Instituto de Biomecánica de Valencia (IBV)	
Amos	Folarin	amos.folarin@kcl.ac.uk	United Kingdom	King's College London	Experience with other IMI projects such as RADAR-CNS
Pablo	Gay	pablo.gay@udg.edu	Spain	University of Girona	AI expertise in healthcare domain.
Kiri	Granger	kiri.granger@camcog.com	United Kingdom	CAMBRIDGE COGNITION LTD	
Christopher	Hardt	hardt@lifeglimmer.com	Germany	LifeGlimmer GmbH	LifeGlimmer GmbH is an international Berlin-based science-driven company that caters advanced solutions for the full research pi
Marieke	Heida	m.heida@mcroberts.nl	Netherlands	McRoberts B.V.	physical activity monitoring devices for patients, to be used in daily life.

# IMI2 - Call 15: Digital endpoints in neurodegenerative and immune-mediated diseases

Jul 18, 2018



First Name	Last Name	Email	Country	Organisation	Briefly, what would you bring to the project in terms of expertise, resources, activities?
Diana	Hodgins	dmh@etb.co.uk	United Kingdom	European Technology for Business Holdings Ltd	We design and manufacture gait monitoring equipment
Bas	Kremer	bas.kremer@tno.nl	Netherlands	TNO	Data analytics/AI, biomarker discovery, immune health data tooling, immunology network
Ioulietta	Lazarou	iouliettalaz@iti.gr	Greece	Centre for Research and Technology Hellas (CERTH) Information Technologies Institute (ITI)	
Vera	Nies	vera.nies@lygature.org	Netherlands	Lygature	
Paula	Petrone	petronepau@gmail.com	Spain	Drayson Health	Clinical data, imaging and drug discovery expertise
Mariona	Pujol	mpujol@idiapjgol.org	Spain	IDIAP Jordi Gol	Partners on EMIF project
Angel Manuel	Rafael	arafael@idimas.es	Spain	IDimas Gestión	Project Management, SME and public Universities related to the topic
Viviana	Roman	rviviana30@yahoo.com	Romania	Institute of Virology-Center of Immunology	
Maria Grazia	Santagati	mariagrazia.santagati@tin.it	Italy	scientific consultancy	networking and project management
Madlen	Schiller	madlen.schiller@ikts.fraunhofer.de	Germany	Fraunhofer	
Sorin	Stircu	sorin.stircu@ehealthline.com	United States	E*HealthLine	Digital transformation platform integrate and standardize real-world health data
Hildrun	Sundseth	hildrun.sundseth@eurohealth.ie	Ireland	European Institute of Women's and Family Health (EIWH)	Patient and societal perspective, how these diseases can affect women and men differently
Lucia	Vaira	lucia.vaira@unisalento.it	Italy	CINI - National Interuniversity Consortium for Informatics	Digital health, connected health, eHealth
Mark	Van Gils	mark.vangils@vtt.fi	Finland	VTT Technical Research Centre of Finland Ltd.	data analysis, algorithm development; experience in analysing data from wearables for neurodegen diseases
Elisa	Vergari	elisa.vergari@ec.europa.eu	Belgium	ERCEA	Scientific Officer
Herman	Verheij	herman.verheij@lygature.org	Netherlands	Lygature	Program Management, Communication, IT Support, Regulatory advice, Patient Engagement

## IMI2 - Call 15: Digital endpoints in neurodegenerative and immune-mediated diseases

Jul 18, 2018



First Name	Last Name	Email	Country	Organisation	Briefly, what would you bring to the project in terms of expertise, resources, activities?
Emre	Yarci	emre.yarci@aifd.org.tr	Turkey	Association of Research-Based Pharmaceutical Companies (AIFD)	
Marek	Zawada	marek.zawada@iqpharma.pl	Poland	IQ Pharma S.A.	Clinical trials/R&D projects/Big Data/ICT solution for monitoring Parkinson's disease using wearable sensors and mobile devices